Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

CLDX

+ Watchlist+ Portfolio

Celldex Therapeutics, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$28.04
52-Week Range
$22.33 – $45.14
Market Cap
$2.16B
P/E (TTM)
—
EPS (TTM)
-4.29
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.33
PEG Ratio
—
Return on Equity
-49.54%
Return on Assets
-30.52%
Gross Margin
0.00%
Operating Margin
-211684.81%
Profit Margin
0.00%
Current Ratio
10.97
Debt/Equity
0.02
Total Debt
$9.87M
Free Cash Flow
$-154.39M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$1.52B

Market Snapshot

About

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted immunotherapies for cancer and other difficult-to-treat diseases. Headquartered in Hampton, New Jersey, the company advances a pipeline of antibody-based therapeutics designed to engage the immune system. Key programs include barzolvolimab for chronic urticaria and mast cell-driven diseases, and CDX-0159 for inflammatory conditions. Celldex leverages its expertise in immunology to create novel treatments addressing significant unmet medical needs.